Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ilaria Attili, Marzia Del Re, Elena Guerini-Rocco, Stefania Crucitta, Pasquale Pisapia, Francesco Pepe, Massimo Barberis, Giancarlo Troncone, Romano Danesi, Filippo de Marinis, Umberto Malapelle & Antonio Passaro. (2021) The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics 21:8, pages 757-766.
Read now
Read now
Hui Yu, Si Sun, Xingjiang Hu, Jinjing Xia, Jialei Wang & Haiquan Chen. (2019) Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. OncoTargets and Therapy 12, pages 6481-6495.
Read now
Read now
Ittai B Muller, Adrianus J de Langen, Elisa Giovannetti & Godefridus J Peters. (2017) Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. OncoTargets and Therapy 10, pages 4535-4541.
Read now
Read now
Articles from other publishers (26)
Cynthia Meyer, Melissa McCoy, Lianbo Li, Bruce Posner & Kenneth D. Westover. (2023) LIMS-Kinase provides sensitive and generalizable label-free in vitro measurement of kinase activity using mass spectrometry. Cell Reports Physical Science 4:10, pages 101599.
Crossref
Crossref
Zoltán Köllő, Miklós Garami, István Vincze, Barna Vásárhelyi & Gellért Karvaly. (2023) Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review. Pharmaceutics 15:1, pages 239.
Crossref
Crossref
Anagha Deshpande & Javier Munoz. (2022) Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. Frontiers in Oncology 12.
Crossref
Crossref
Aleksandra Grela-Wojewoda, Renata Pacholczak-Madej, Agnieszka Adamczyk, Michał Korman & Mirosława Püsküllüoğlu. (2022) Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. International Journal of Molecular Sciences 23:5, pages 2815.
Crossref
Crossref
Akhileshwar Kumar Srivastava, Dhruv Kumar, Divya Singh & Rajesh Kumar Singh. 2022. Xenobiotics in Chemical Carcinogenesis. Xenobiotics in Chemical Carcinogenesis
245
259
.
Saurav Panicker, Sivaramakrishnan Venkatabalasubramanian, Surajit Pathak & Satish Ramalingam. (2021) The impact of fusion genes on cancer stem cells and drug resistance. Molecular and Cellular Biochemistry 476:10, pages 3771-3783.
Crossref
Crossref
V. Subbiah, S. Kuravi, S. Ganguly, D.R. Welch, C.J. Vivian, M.U. Mushtaq, A. Hegde, S. Iyer, A. Behrang, S.M. Ali, R.W. Madison, J.M. Venstrom, R.A. Jensen, J.P. McGuirk, H.M. Amin & R. Balusu. (2021) Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open 6:4, pages 100172.
Crossref
Crossref
Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow & Giandomenico Roviello. (2020) Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers 12:11, pages 3293.
Crossref
Crossref
Chao Zhang, Natasha B. Leighl, Yi-Long Wu & Wen-Zhao Zhong. (2019) Emerging therapies for non-small cell lung cancer. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Elena Poddubskaya, Alexey Bondarenko, Alexander Boroda, Evgenia Zotova, Alex Glusker, Svetlana Sletina, Luidmila Makovskaia, Philipp Kopylov, Marina Sekacheva, Alexey Moisseev & Madina Baranova. (2019) Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. Frontiers in Oncology 9.
Crossref
Crossref
Peter J. Houghton & Raushan T. Kurmasheva. (2019) Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews 71:4, pages 671-697.
Crossref
Crossref
Michela Terlizzi, Chiara Colarusso, Aldo Pinto & Rosalinda Sorrentino. (2019) Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacology & Therapeutics 202, pages 140-148.
Crossref
Crossref
Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu & Daiying Zuo. (2019) Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemotherapy and Pharmacology 84:4, pages 679-688.
Crossref
Crossref
Hong Kyu Lee, Mi Jung Kwon, Jinwon Seo, Jeong Won Kim, Mineui Hong, Hye-Rim Park, Soo Kee Min, Ji-Young Choe, Yong Joon Ra, Seung Hun Jang, Yong Il Hwang, Ho Young Kim & Kyueng-Whan Min. (2019) Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer. Pathology - Research and Practice 215:3, pages 459-465.
Crossref
Crossref
Daniel de Klerk, Richard Honeywell, Gerrit Jansen & Godefridus Peters. (2018) Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers 10:12, pages 503.
Crossref
Crossref
Zhichao Liu, Youting Bao, Butuo Li, Xindong Sun & Linlin Wang. (2018) Does ALK‐rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non‐small‐cell lung cancer? Case report and literature review. Clinical and Translational Medicine 7:1.
Crossref
Crossref
Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Morena Fasano, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello & Floriana Morgillo. (2018) Role and targeting of anaplastic lymphoma kinase in cancer. Molecular Cancer 17:1.
Crossref
Crossref
Shun-ichiro Kageyama, Keiji Nihei, Katsuyuki Karasawa, Takeshi Sawada, Fumiaki Koizumi, Shigeo Yamaguchi, Shunsuke Kato, Hidehiro Hojo, Atsuhi Motegi, Katsuya Tsuchihara & Tetsuo Akimoto. (2018) Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Oncotarget 9:27, pages 19368-19378.
Crossref
Crossref
Tiziana Vavalà & Silvia Novello. (2018) Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology 10, pages 175883591878936.
Crossref
Crossref
Muhammad Latif, Zaman Ashraf, Sulman Basit, Abdul Ghaffar, Muhammad Sohail Zafar, Aamer Saeed & Sultan Ayoub Meo. (2018) Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. RSC Advances 8:30, pages 16470-16493.
Crossref
Crossref
Nele Van Der Steen, Yves Mentens, Marc Ramael, Leticia G. Leon, Paul Germonpré, Jose Ferri, David R. Gandara, Elisa Giovannetti, Godefridus J. Peters, Patrick Pauwels & Christian Rolfo. (2018) Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clinical Lung Cancer 19:1, pages 35-41.
Crossref
Crossref
H. Tsui, Q. Zeng, K. Chen & X. Zhang. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
408
446
.
Hangping Wei, Fangming Du, Yifang Lu, Juan Wei & Xiaofang Dong. (2016) Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments. SpringerPlus 5:1.
Crossref
Crossref
Sebastien Dejust, David Morland, Guillaume Fabre, Alain Prevost & Dimitri Papathanassiou. (2016) 18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non–small Cell Lung Cancer. Clinical Nuclear Medicine 41:11, pages 879-880.
Crossref
Crossref
Mei Han, Chengyan Wang, Yinchun Ji, Zilan Song, Li Xing, Yi Su, Xisheng Wang, Ao Zhang, Jing Ai & Meiyu Geng. (2016) Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core. Bioorganic & Medicinal Chemistry Letters 26:22, pages 5399-5402.
Crossref
Crossref
Natasha S. Latysheva & M. Madan Babu. (2016) Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Research 44:10, pages 4487-4503.
Crossref
Crossref